News & AnalysisNuvalent garners $135m Series BNuvalent Inc, a biotechnology company, has closed $135 million in Series B financing.ByIris Dorbian11 May 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs